Report Industry Investment Rating No relevant content provided. Core Viewpoints of the Report - The overall situation of the market is complex, with different trends in various sectors. In the agricultural products sector, the spot market of peanuts is stable but weak, and the short - term trend of the futures market is still weak. The trading volume of edible oils has increased, but the market lacks positive support. The sugar market is affected by international and domestic factors, and the futures price is under pressure. The corn market shows a divergence between the spot and futures markets. The pig and egg markets have their own characteristics in terms of supply, demand, and price trends. In the energy and chemical sector, the urea market is in a situation of strong supply and weak demand, and the price is under pressure. The caustic soda market has a weak fundamental situation. The coking coal and coke markets are affected by factors such as production recovery and downstream demand, showing a weak and volatile trend. In the industrial metals sector, the copper and aluminum markets are affected by factors such as supply and demand and inventory, and the price increase momentum is in doubt. The alumina market is under pressure due to supply recovery. The steel market is affected by factors such as production, demand, and inventory, and the price is under short - term pressure. The ferroalloy market is affected by supply and demand and cost factors, and the medium - term trend is bearish. The lithium carbonate market is in an oversupply situation, and the price is in a bottom - stage range. In the option and financial sector, the stock index shows an upward trend, but there are differences in the 3400 - point area. The option market has different performance in different varieties, and investors need to take corresponding strategies according to different market conditions [11][13][15]. Summary by Relevant Catalogs 1. Market Price Changes - **Chemical Industry**: On June 13, 2025, compared with the previous day, the prices of some chemical products changed. For example, the price of coking coal decreased by 1.50 to 765.00, with a decline of 0.196%; the price of natural rubber increased by 110.0 to 13,695.00, with an increase of 0.810% [3]. - **Agricultural Products**: The prices of some agricultural products also changed. For example, the price of yellow soybean No.1 increased by 5.0 to 4,203.00, with an increase of 0.119%; the price of No.1 cotton decreased by 85.0 to 13,435.00, with a decline of 0.629% [3]. 2. Macroeconomic News - **Sino - US Economic and Trade Consultation**: The first meeting of the Sino - US economic and trade consultation mechanism was held under the strategic guidance of the two heads of state. The two sides reached a principle agreement on the measures framework for implementing the important consensus of the two heads of state's phone call on June 5 and consolidating the results of the Geneva economic and trade talks, and made new progress in addressing each other's economic and trade concerns. The Chinese side opposes unilateral tariff - increasing measures and hopes that the US side will abide by WTO rules and jointly promote the stable and sustainable development of Sino - US economic and trade relations [6]. - **Financial Support for Fujian**: The central bank and the foreign exchange administration jointly issued measures to support Fujian in exploring a new path for cross - strait integrated development and building a cross - strait integrated development demonstration zone, including supporting the construction of a multi - level cross - strait financial market [6]. - **Economic Data**: In May, the real economy continued to grow, with the sales revenue of the manufacturing industry accounting for 30.1% of the national enterprise sales. The sales revenue of the equipment manufacturing industry increased by 7.5% year - on - year [7]. - **Stock Market Trends**: Since 2025, the domestic innovative drug sector has rebounded, and as of June 12, the Wind innovative drug index has increased by 27.46% year - to - date [7]. 3. Morning Meeting Views on Major Varieties Agricultural Products - **Peanuts**: The peanut spot market is stable but weak. The short - term futures market will continue to fluctuate weakly, waiting for new drivers [11]. - **Edible Oils**: The trading volume of edible oils has increased, but the market lacks positive support, and it is recommended to short on rebounds [11]. - **Sugar**: The sugar futures price has broken through the support level. The international sugar price is weak, and the domestic spot price has been adjusted. It is recommended to hold short positions but beware of technical rebounds [11]. - **Corn**: The corn market shows a divergence between the spot and futures markets. The spot market is strong, while the futures market is under pressure. It is recommended that long - position holders take partial profits in the 2360 - 2380 range [11]. - **Pigs**: The pig price is stable, the supply is relatively stable, and the futures market has a weak rebound [13]. - **Eggs**: The egg price is stable but weak. The futures market is under pressure due to factors such as high - temperature weather and inventory [13]. Energy and Chemicals - **Urea**: The domestic urea market price is weak. The supply is high, the demand is weak, and the futures price is under pressure. It is necessary to pay attention to port inventory changes and agricultural demand replenishment [13]. - **Caustic Soda**: The fundamental situation of the caustic soda market is weak, and the 2509 contract is recommended to be treated with a bearish mindset [13]. - **Coking Coal**: The coking coal market is affected by production recovery and downstream demand, showing a weak and volatile trend [13][15]. Industrial Metals - **Copper and Aluminum**: The copper and aluminum markets are affected by factors such as supply and demand and inventory. The price increase momentum is in doubt, and it is not advisable to chase high prices [15]. - **Alumina**: The alumina market is under pressure due to supply recovery, and the 2509 contract may continue to be under pressure [15]. - **Steel**: The steel market is affected by factors such as production, demand, and inventory, and the price is under short - term pressure [15]. - **Ferroalloys**: The ferroalloy market is affected by supply and demand and cost factors, and the medium - term trend is bearish [16]. - **Lithium Carbonate**: The lithium carbonate market is in an oversupply situation, and the price is in a bottom - stage range. It is recommended to wait and see and beware of market fluctuations [16]. Option Finance - **Stock Index**: The stock index shows an upward trend, but there are differences in the 3400 - point area. It is recommended that unilateral long - position holders reduce positions on rallies and operate in a rolling manner [16][17]. - **Options**: The option market has different performance in different varieties. Trend investors are recommended to defend, and volatility investors are recommended to buy wide - straddle strategies after the volatility decline [18].

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing positive momentum, driven by significant developments in innovative drug approvals and collaborations, particularly highlighted during the recent ASCO annual meeting and the announcement of potential licensing deals by major companies [1][2]. Group 1: Market Performance - As of June 13, 2025, the CSI Hong Kong Pharmaceutical and Health Comprehensive Index (930965) saw notable increases in key stocks, including WuXi Biologics (02269) up by 5.41%, and Innovent Biologics (01801) up by 3.53% [1]. - The Hong Kong Medical ETF (513700) rose by 1.28%, with a cumulative increase of 12.57% over the past week as of June 12, 2025 [1][2]. Group 2: Industry Developments - On June 12, 2025, China Biopharmaceutical announced at the 46th Goldman Sachs Global Healthcare Conference in Miami that it has received multiple collaboration intentions for its products, indicating a significant upcoming licensing deal [1]. - The ASCO annual meeting showcased the competitiveness and innovation of Chinese pharmaceutical companies, with several impressive results and data presentations [2]. Group 3: ETF and Index Information - The Hong Kong Medical ETF (513700) effectively tracks the CSI Hong Kong Pharmaceutical and Health Comprehensive Index, which includes 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [2]. - The top ten weighted stocks in the CSI Hong Kong Pharmaceutical and Health Comprehensive Index as of May 30, 2025, include companies like BeiGene (06160) and WuXi Biologics (02269), collectively accounting for 60.77% of the index [3].

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Core Viewpoint - The approval of the innovative drug Olanidavir, targeting the PB2 subunit of the influenza A virus, marks a significant advancement in global influenza prevention and treatment, showcasing China's capability in drug innovation [1][3][6] Group 1: Drug Development and Approval - Olanidavir, developed by the Guangzhou National Laboratory, is the world's first drug targeting the PB2 subunit of the influenza A virus, receiving approval from the National Medical Products Administration [1][3] - The drug's development involved collaboration among multiple institutions, including Guangzhou Medical University and the National Respiratory Medicine Center, integrating resources from various disciplines [2][5] Group 2: Mechanism and Efficacy - Olanidavir employs a unique "cap-snatching" mechanism, differing from existing antiviral drugs, and has shown significant clinical efficacy, reducing symptom relief time by nearly 40% compared to placebo [3][4] - The drug has a low resistance mutation rate, with suspected resistance occurrences of 0% and 1.6% in clinical phases II and III, respectively, and is effective against resistant "super influenza viruses" [4] Group 3: Broader Implications and Future Directions - Olanidavir is not only effective against seasonal influenza but also shows potential against highly pathogenic avian influenza viruses like H7N9 and H5N6, providing tools for pandemic preparedness [4] - The Guangzhou National Laboratory aims to further enhance research capabilities and develop broad-spectrum vaccines and drugs, leveraging AI and big data for innovation [5][6]

Group 1 - The Hang Seng Medical Index ETF has shown active trading with a turnover of 17.71% and a transaction volume of 46.90 million yuan, indicating a vibrant market activity [3] - Over the past six months, the Hang Seng Medical Index ETF has experienced a significant growth in scale, increasing by 51.07 million yuan, ranking first among comparable funds [3] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 26.52, which is in the 8th percentile over the past three years, indicating a historical low valuation [3] Group 2 - As of May 29, the number of globally approved new drugs in China has reached 54, with 34 being domestic innovative drugs and 20 imported, showing a strong growth in domestic innovation [3] - The approval of domestic innovative drugs in 2024 is projected to be 37, while the number approved in the first half of this year is close to last year's total, highlighting a rapid increase in innovation [3] - Institutions believe that the competitiveness of domestic innovative drugs in the global market is rising, and international investors are increasingly confident in Chinese innovative pharmaceutical companies [4]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [5]. Core Viewpoints - The investment enthusiasm for innovative drugs remains high, with a focus on genuine innovation and stable high-dividend stocks. The recent ASCO annual meeting showcased the competitiveness of Chinese pharmaceutical companies in new drug development, leading to a positive market response [2][23]. - The report suggests focusing on companies with strong clinical progress and international expansion capabilities, such as Yifang Biotech-U, Zai Lab-U, Rongchang Biotech (A+H), and Xinlitai [2][24]. - Given the complex macroeconomic environment and recent financial policies aimed at stabilizing the market, leading pharmaceutical companies with robust growth and high dividend characteristics are seen as attractive investment opportunities [2][24]. Summary by Sections Market Review - Last week, the pharmaceutical and biotechnology index rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points but underperforming the ChiNext index by 1.53 percentage points, ranking 17th among 31 sub-industries [1][18]. - The Hong Kong Hang Seng Healthcare Index increased by 6.1%, outperforming the Hang Seng China Enterprises Index by 3.76 percentage points [1][18]. Company Updates - Recent developments include the IND application for HRS-4508 by Heng Rui Pharmaceutical and ongoing clinical trials for HMPL-306 and HS-10374 by Hutchison China MediTech, as well as HS-10506 and CM518D1 by Hansoh Pharmaceutical and ConvaTec, respectively [32][34]. High Dividend Stocks - The report identifies several high-dividend stocks in the pharmaceutical sector, including Huate Dain, Jichuan Pharmaceutical, Kefu Medical, Xizang Pharmaceutical, Jiangzhong Pharmaceutical, and others, which are expected to benefit from recent monetary and fiscal policies [2][24][25]. R&D Progress - The report highlights the ongoing clinical trials and regulatory approvals for various innovative drugs, indicating a robust pipeline for the companies involved [32][34]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments. Key recommendations include Heng Rui Pharmaceutical, Mindray Medical, United Imaging Healthcare, and Yiyuan Medical [29].

Group 1 - China Pacific Insurance launched a private equity fund with a target size of 20 billion yuan, emphasizing long-term investment principles [1] - China Chengtong's subsidiary subscribed to the initial shares of three ETFs, signaling strong confidence in the long-term value of state-owned enterprises [1] - The approval of the first batch of new floating fee rate funds indicates a shift towards performance-based management fees, enhancing the attractiveness of long-term investments [1] Group 2 - The electricity trading market in China is undergoing significant changes due to the implementation of market-oriented pricing reforms for renewable energy [2] - There has been a fourfold increase in consultation requests and a twofold increase in order volume for electricity trading services, driven by the entry of renewable energy into the market [2] - AI technology is increasingly integrated into the electricity trading process, enhancing decision-making and market operations [2] Group 3 - The innovative drug sector, particularly in Hong Kong, has shown remarkable performance, with several ETFs in this category rising over 50% this year [3] - Domestic innovative drugs are gaining global competitiveness, attracting international investors and marking a transition from "follower" to "leader" in the market [3] - Hong Kong is identified as a key market for investing in innovative drugs, with a focus on globally competitive companies [3] Group 4 - Multiple economic stimulus policies are expected to be introduced, focusing on sectors like "two new" and "two heavy" industries, as well as stabilizing foreign trade [4] - The issuance of new equity funds has seen a resurgence, with several funds raising over 1 billion yuan since June [4] - There is a notable trend of funds concentrating on high-performing managers, reflecting a shift in investor preferences [4] Group 5 - The popularity of floating management fee funds is on the rise, with one fund reaching its 2 billion yuan cap within six days of launch [5] - The A-share market's structural opportunities and positive long-term trends are contributing to the demand for actively managed products [5] - Fund managers are particularly optimistic about investments in innovative drugs and AI technologies [5] Group 6 - Infrastructure investment has been robust this year, supported by proactive fiscal policies and accelerated bond issuance [6] - Despite positive fundamentals, some high-frequency data related to construction funding shows weaknesses, indicating untapped investment potential [6] - Mid-cap stocks have performed well, with several thematic funds seeing significant net value increases [6] Group 7 - The issuance of new floating fee rate funds has led to a slight recovery in the equity fund market, with 22 new funds established in the first week of June [7] - The total issuance scale for new funds reached 31.01 billion yuan, with bond funds making up over half of the total [7] - There is a noticeable trend of limited enthusiasm for equity products, as indicated by the smaller average size of newly established stock funds [7] Group 8 - Jiangsu Province has introduced measures to boost consumption, including allowing family members to withdraw housing provident fund for down payments [8] - Various cities have adjusted housing provident fund policies to enhance its support for housing consumption [8] Group 9 - Newly listed stocks in the Hong Kong market have shown impressive gains, with some stocks increasing by over 164% since their IPO [9] - Despite the strong performance of new stocks, market volatility poses risks, and investors should be cautious of potential price corrections [9] - The expiration of lock-up periods for certain shareholders may lead to short-term pressure on stock prices [9] Group 10 - The brain-computer interface sector is experiencing unprecedented growth, with significant advancements in technology and clinical applications [10] - The first batch of flexible high-throughput semi-invasive brain-computer systems has been successfully implanted, showing over 98% effectiveness in signal collection [10] - 2025 is anticipated to be a pivotal year for clinical applications in this field, with multiple companies making progress in their technologies [10]

Core Insights - The 2025 ASCO Annual Meeting will showcase significant research results from domestic innovative drugs, highlighting their potential in oncology treatments [1] Group 1: Clinical Data and Drug Performance - The TROP2 ADC SKB264 from Kelun-Biotech reported a 59.3% overall response rate (ORR) and a 91.4% disease control rate (DCR) in a Phase II trial for non-small cell lung cancer (NSCLC) [2] - The median progression-free survival (mPFS) for the same patient group was 15.0 months, with ORR varying by PD-L1 expression levels: 47.1% for TPS<1%, 68.1% for TPS≥1%, and 77.8% for TPS≥50% [2] - Compared to previous data, the ORR decreased from 72.7% to 59.3% in a larger sample size [2] - SKB264 demonstrated superior efficacy over other PD-1/VEGF dual antibodies, with ORR of 54.5% for SSGJ-707 and 47% for Ivosidenib [3] Group 2: Safety and Adverse Effects - The incidence of grade 3 or higher adverse reactions for SKB264 was 40%, higher than SSGJ-707's 24.1% and Ivosidenib's 29% [3] - However, the discontinuation rate due to adverse effects for SKB264 was 0%, lower than Ivosidenib's 2% and SSGJ-707's 6% [3] Group 3: Comparative Efficacy in EGFR Mutant NSCLC - In a separate study for EGFR mutant NSCLC, SKB264 showed a 45.1% ORR and mPFS of 6.9 months, statistically significant compared to Docetaxel [4] - Despite a decrease in ORR and mPFS in larger sample sizes, SKB264 still outperformed Dato-DXd (43%) and HER3-DXd (35.2%) in efficacy [4] - Other domestic competitors also showed promising results, with Ivosidenib achieving an ORR of 50.6% and BL-B01D1 reaching 52.5% in their respective trials [4][5]

Core Viewpoint - The 2025 ASCO Annual Meeting will showcase significant research achievements of domestic innovative drugs, highlighting their potential in oncology treatment [1] Group 1: Innovative Drug Highlights - Several innovative drug molecules with first-in-class or best-in-class potential will present data, including IBI363 from Innovent Biologics, SKB264 from Kelun-Biotech, and others [1] - IBI363 is the world's first next-generation IO dual antibody designed with IL 2α bias, showing promising efficacy in treating IO-resistant tumors such as NSCLC, melanoma, and CRC [2] Group 2: Clinical Data and Efficacy - In a Phase I clinical study, IBI363 demonstrated an overall response rate (ORR) of 43.3% and a disease control rate (DCR) of 90.0% in squamous NSCLC patients at a 3 mg/kg dosage, with a median progression-free survival (mPFS) of 7.3 months [2] - For adenocarcinoma patients previously treated with PD-(L)1 therapy, the 3 mg/kg group showed an ORR of 76.0% and a DCR of 90.0%, with an mPFS of 4.2 months [2] Group 3: Comparative Efficacy - IBI363 exhibited significant clinical activity in IO-resistant lung squamous and adenocarcinoma patients, outperforming existing therapies such as docetaxel and various immune combination treatments [3] Group 4: Colorectal Cancer Potential - IBI363 also shows promise in late-line CRC treatment, with clinical studies indicating an overall survival (OS) of 16.1 months for patients treated with IBI363 monotherapy [5][6] - Compared to standard treatments like TAS-102 combined with bevacizumab, IBI363 demonstrated superior survival outcomes in patients with worse baseline characteristics [6]

Group 1 - The Hong Kong pharmaceutical sector has seen a significant rise, with companies like Zai Lab and SiHuan Pharmaceutical increasing by over 7% [1] - The Hang Seng Innovation Drug ETF (159316) and the Hong Kong Stock Connect Pharmaceutical ETF (513200) both tracked indices that rose over 1%, reaching new highs for the year [1] - In May 2025, Chinese innovative pharmaceutical companies showcased 71 original research results at the ASCO conference, highlighting their international leadership in innovation and research [1] Group 2 - Recent approvals for multiple innovative drugs in China cover various cutting-edge treatment areas, indicating a significant enhancement in the ability of domestic innovative drugs to transition from research to commercialization [1] - Some innovative products have achieved a positive feedback loop in R&D investment returns under the current domestic innovation payment system, with sales reaching new highs [1] - The Hang Seng Innovation Drug ETF (159316) is the first ETF tracking the Hang Seng Stock Connect Innovation Drug Index, focusing on companies involved in innovative drug research, development, and production [2]